recent
pandem
demonstr
potenti
vulner
human
popul
novel
influenza
virus
recent
increas
interest
effort
develop
effect
antiinfluenza
agent
new
product
enter
clinic
studi
review
highlight
limit
armamentarium
licens
influenza
agent
discuss
novel
compound
strategi
enter
clinic
studi
may
therefor
immin
avail
treat
clinician
march
novel
strain
influenza
emerg
caus
increas
report
influenzalik
ill
north
america
initi
report
case
occur
mexico
citi
seen
epicent
influenza
pandem
world
first
year
initi
report
suggest
high
mortal
rate
although
subsequ
analysi
suggest
earli
report
like
inaccur
attribut
death
novel
substanti
underestim
total
number
individu
infect
mild
case
diseas
may
countri
oversea
territori
commun
worldwid
report
laboratoryconfirm
case
pandem
influenza
includ
least
death
contrast
season
influenza
influenza
affect
younger
healthier
popul
viral
glycoprotein
hemagglutinin
ha
neuraminidas
na
main
target
immun
respons
influenza
vaccin
elicit
immun
respons
glycoprotein
vari
continu
result
antigen
drift
shift
given
time
produc
antigen
appropri
immunogen
product
antivir
drug
princip
countermeasur
emerg
influenza
virus
current
licens
antiinfluenza
medic
consist
four
drug
two
oral
adamantan
amantadin
rimantadin
two
na
inhibitor
nai
oral
drug
oseltamivir
inhal
medic
zanamivir
ribavirin
licens
influenza
avail
mani
countri
antiinfluenza
activ
resist
influenza
virus
amantadin
rimantadin
occur
spontan
emerg
rapidli
treatment
season
isol
resist
compound
although
still
maintain
sensit
oseltamivir
zanamivir
season
isol
prior
resist
oseltamivir
although
remain
sensit
amantadin
rimantadin
zanamivir
influenza
isol
resist
amantadin
rimantadin
isol
addit
resist
oseltamivir
peramivir
limit
armamentarium
effect
antiinfluenza
agent
increas
resist
highlight
potenti
vulner
human
popul
novel
influenza
virus
overlook
recent
year
patent
public
aspect
therapeut
antiinfluenza
agent
develop
antiinfluenza
agent
occur
follow
area
adamantanelik
compound
muscarin
acetylcholin
receptor
antagonist
antisens
sirna
mirna
compound
strategi
involv
approach
still
preclin
studi
enter
clinic
studi
figur
show
mechan
action
major
compoundsclass
clinic
studi
review
focu
compound
strategi
enter
clinic
evalu
may
therefor
immin
avail
treat
clinician
furthermor
histori
suggest
influenza
pandem
recur
sever
time
centuri
strategi
appli
emerg
influenza
strain
review
antivir
strategi
easili
implement
novel
influenza
viru
util
exist
licens
antivir
trial
support
use
oseltamivir
treatment
adult
human
influenza
present
within
h
develop
fever
respiratori
symptom
constitut
symptom
random
patient
placebo
oseltamivir
mg
bid
oseltamivir
mg
bid
primari
endpoint
clinic
resolut
symptom
studi
oseltamivir
treatment
suggest
decreas
nasal
viral
titer
compar
placebo
although
neither
studi
reach
statist
signific
one
studi
suggest
dosedepend
gorvorkova
et
al
evalu
oseltamivir
nai
avian
influenza
virus
mous
model
demonstr
doserel
reduct
viru
titer
lung
avian
influenza
virus
maximum
suppress
seen
highest
dose
test
mgkgday
test
avian
influenza
murin
studi
indic
higher
oseltamivir
dose
mgkgday
instead
mgkgday
prolong
administr
day
instead
day
necessari
achiev
antivir
surviv
effect
avian
influenza
viru
earli
develop
studi
human
oseltamivir
dosag
regimen
mg
twice
daili
shown
well
toler
effort
determin
higher
dose
oseltamivir
convey
clinic
benefit
multicent
studi
initi
asia
us
june
compar
standardv
highdos
regimen
defin
mg
twice
daili
adult
normal
renal
function
oseltamivir
day
sever
season
avian
influenza
studi
recent
complet
enrol
although
result
yet
avail
clinicaltrialsgov
identifi
separ
studi
compar
mg
vs
mg
twice
daili
day
subject
influenza
intens
care
unit
initi
novemb
clinicaltrialsgov
identifi
pend
result
studi
definit
recommend
higher
oseltamivir
dose
treatment
influenza
novel
strain
support
clinic
data
paradigm
combin
antivir
effect
control
viral
replic
explor
influenza
long
becam
establish
tenant
treatment
hiv
vitro
studi
dual
antivir
evalu
amantadineoseltamivir
amantadineribavirin
rimantadinenai
zanamivir
oseltamivir
peramivir
ribavirinadamantan
amantadin
rimantadin
ribavirinnai
oseltamivir
peramivir
dual
nai
combin
involv
novel
agent
favipiraviroseltamivir
dual
antivir
combin
evalu
anim
studi
includ
amantadineoseltamivir
amantadineribavirin
rimantadin
oseltamivir
ribavirinnai
oseltamivir
peramivir
vivo
dual
combin
synergist
although
simpli
addit
synergi
oseltamiviramantadin
combin
amantadineresist
influenza
viru
dual
nai
shown
mix
result
synergi
shown
certain
dose
studi
demonstr
potenti
antagon
combin
amantadin
oseltamivir
reduc
emerg
oseltamivirand
amantadineresist
virus
vivo
tripl
antivir
combin
shown
increas
antivir
activ
reduct
ec
drug
compar
activ
doubl
combin
singl
agent
tripl
antivir
combin
virus
resist
one
compon
amantadin
resist
shown
dose
effect
compon
suggest
incorpor
resist
compound
still
contribut
antivir
efficaci
oral
rimantadin
plu
either
nebul
zanamivir
salin
placebo
evalu
treatment
adult
hospit
influenza
subject
random
rimantadin
zanamivir
like
either
cough
mild
cough
third
day
treatment
although
differ
viral
shed
durat
hospit
oxygen
requir
clinic
outcom
phase
ii
trial
clinicaltrialsgov
identifi
way
franc
compar
efficaci
safeti
combin
oseltamivirzanamivir
vs
monotherapi
agent
help
determin
ad
benefit
combin
nai
anoth
studi
compar
oseltamivirzanamivir
oseltamiviramantadin
vs
oseltamivir
monotherapi
help
determin
clinic
benefit
synergi
seen
vivo
clinicaltrialsgov
identifi
two
studi
evalu
tripl
antivir
therapi
first
intern
multicent
studi
compar
antivir
effect
tripledrug
regimen
fixeddos
combin
amantadin
ribavirin
oseltamivir
vs
oseltamivir
alon
clinicaltrialsgov
identifi
second
studi
evalu
amantadin
ribavirinoseltamivir
compar
nai
oseltamivir
zanamivir
monotherapi
immunocompromis
patient
clinicaltrialsgov
identifi
addit
clinic
studi
combin
therapi
need
result
studi
avail
definit
recommend
combin
antivir
support
clinic
data
use
current
licens
medic
treatment
would
significantli
shorten
develop
time
new
treatment
agent
categori
would
like
establish
safeti
profil
potenti
would
patent
may
make
medic
inexpens
therefor
wide
avail
nitazoxanid
current
fit
categori
nitazoxanid
licens
antiprotozo
agent
antiprotozo
activ
nitazoxanid
believ
due
inhibit
pyruvicferredoxin
oxidoreductas
por
enzym
essenti
anaerob
energi
metabol
nitazoxanid
current
licens
treatment
diarrhea
caus
giardia
lamblia
cryptosporidium
parvum
nitazoxanid
metabolit
tizoxanid
caus
concentrationdepend
inhibit
influenza
viru
replic
ec
valu
strain
test
mean
c
max
licens
dose
nitazoxanid
class
agent
shown
act
posttransl
level
select
block
matur
viral
ha
impair
ha
intracellular
traffick
insert
protein
host
plasma
membran
base
data
phase
ii
studi
initi
earli
treatment
uncompl
influenza
clinicaltrialsgov
identifi
develop
new
formul
current
licens
antivir
may
shorten
develop
time
would
safeti
data
primari
compound
although
differ
dose
c
max
may
portend
differ
toxic
addit
clinician
may
familiar
compound
increas
accept
first
report
deriv
acid
dana
sialic
acid
analogu
abl
inhibit
na
activ
influenza
b
virus
use
novel
computerassist
drug
design
dana
optim
enzym
activesit
bind
influenza
na
result
acid
zanamivir
subsequ
clinic
studi
show
oral
bioavail
zanamivir
although
parenter
administr
zanamivir
provid
c
max
time
higher
inhal
formul
l
respect
inhal
powder
formul
prove
suffici
treatment
outpati
influenza
mous
model
influenza
suggest
viral
shed
mortal
decreas
increas
dose
zanamivir
data
obtain
subject
avian
influenza
suggest
sever
diseas
associ
viremia
inhal
dri
powder
zanamivir
system
absorb
therefor
unknown
inhal
zanamivir
suffici
sever
diseas
although
initi
develop
inhal
powder
previou
clinic
studi
evalu
efficaci
zanamivir
formul
includ
nebul
iv
formul
recent
pandem
reinvigor
interest
parenter
nai
singlearm
openlabel
trial
evalu
safeti
data
iv
zanamivir
clinicaltrialsgov
identifi
addit
iv
zanamivir
avail
glaxosmithklin
compassionateus
expandedaccess
program
serum
plasma
treatment
infecti
diseas
special
case
serum
therapi
first
effect
antimicrobi
therapi
preced
use
sulfonamid
penicillin
safeti
plasma
contain
influenza
antibodi
reason
well
establish
current
plasma
suppli
clinic
indic
contain
antibodi
season
vaccin
infect
immun
plasma
may
collect
faster
new
small
molecul
develop
therapi
plasma
may
therefor
consid
therapeut
emerg
diseas
therapeut
efficaci
f
fragment
demonstr
balbc
mous
model
given
lethal
dose
viru
model
mice
receiv
ip
inject
f
fragmentsmous
normal
hors
antibodi
control
h
infect
f
gave
protect
death
compar
antibodyneg
control
nonimmun
equin
antibodi
surviv
elevenweekold
mice
inject
ip
mous
immun
serum
subsequ
challeng
mld
demonstr
surviv
compar
salin
control
multipl
small
clinic
trial
conduct
soviet
union
report
convalesc
plasma
ivig
effect
treatment
influenza
studi
often
small
random
consist
benefici
effect
suggest
antibodybas
therapi
may
alter
cours
diseas
enough
afford
clinic
benefit
metaanalysi
use
plasma
therapi
influenza
compil
data
studi
involv
patient
administ
convalesc
plasma
typic
volum
plasma
serum
administ
ml
studi
random
blind
intervent
standard
volum
ha
antibodi
titer
overal
crude
casefat
rate
among
treat
patient
among
control
effort
collect
plasma
hightit
antibodi
current
way
treatment
studi
schedul
open
enrol
clinicaltrialsgov
identifi
plasmabas
therapi
collect
human
donor
rel
expens
improv
manufactur
cost
achiev
increas
economi
scale
monoclon
antibodi
influenza
potenti
improv
cost
economi
scale
although
monoclon
antibodi
still
preclin
develop
yet
start
clinic
trial
peramivir
also
known
highli
select
inhibitor
influenza
b
viru
na
unlik
oseltamivir
zanamivir
peramivir
cyclopentan
structur
design
improv
bind
activ
site
na
enzym
preclin
model
predict
good
bioavail
oncedaili
dose
clinic
studi
reveal
oral
bioavail
roughli
larg
dose
abl
overcom
poor
bioavail
phase
ii
studi
show
significantli
reduc
viral
shed
dose
mg
daili
given
need
parenter
nai
agent
clinic
studi
iv
im
peramivir
began
four
iv
two
im
studi
complet
none
publish
date
summar
fda
fact
sheet
health
care
profession
uncompl
influenza
singl
iv
dose
peramivir
better
placebo
time
allevi
symptom
although
true
singl
im
dose
comparison
oseltamivir
peramivir
demonstr
superior
primari
endpoint
allevi
symptom
although
peramivir
still
evalu
licens
studi
due
pandem
us
fda
made
iv
peramivir
avail
mechan
call
emerg
use
author
eua
first
eua
issu
unapprov
drug
unapprov
drug
use
peramivir
restrict
confirm
infect
especi
subject
high
risk
may
toler
standard
antivir
develop
oseltamivir
resist
due
also
confer
clinic
signific
peramivir
resist
like
nai
laninamivir
previous
known
sialic
acid
analogu
activ
varieti
influenza
b
virus
laninamivir
similar
structur
zanamivir
methyl
substitut
hydrogen
one
sidechain
ic
laninamivir
gener
higher
zanamivir
howev
laninamivir
acyl
carbon
chain
posit
form
prodrug
halflif
activ
drug
laninamivir
significantli
increas
balbc
mous
model
treatment
zanamivir
laninamivir
h
infect
influenza
apr
show
surviv
respect
current
develop
inhal
formul
doseescal
phase
studi
singl
inhal
dose
serum
halflif
h
gave
halflif
h
activ
compound
laninamivir
mg
mous
studi
suggest
rapidli
metabol
laninamivir
respiratori
tract
lung
halflif
h
laninamivir
present
lung
sever
day
like
gradual
absorb
account
long
halflif
h
mice
studi
compar
laninamivir
given
iv
mice
halflif
h
daiichi
sankyo
report
result
phase
iii
studi
august
although
date
studi
publish
approxim
adult
patient
confirm
influenza
b
random
receiv
either
mg
laninamivir
singl
inhal
dose
mg
oseltamivir
twice
daili
day
primari
endpoint
trial
time
symptom
resolut
dose
laninamivir
effect
oseltamivir
separ
phase
iiiii
studi
perform
children
random
mg
laninamivir
oseltamivir
mgkg
twice
daili
day
report
trend
toward
faster
time
allevi
influenza
symptom
laninamivir
group
date
data
publish
cellsurfac
sialic
acid
predominantli
nacetylneuramin
acid
host
cell
receptor
influenza
b
virus
one
potenti
mechan
minim
infect
influenza
virus
remov
target
cell
surfac
bacteri
sialidas
clone
actinomyc
viscosu
coupl
heparinbind
sequenc
deriv
human
protein
amphiregulin
serv
respiratori
epitheliumanchor
domain
demonstr
activ
isol
retain
activ
oseltamivirand
zanamivirresist
virus
mous
model
control
group
mortal
given
h
infect
effect
prevent
death
slightli
less
effect
given
h
infect
addit
mous
model
coinfect
influenza
streptococcu
pneumonia
treatment
associ
lower
bacteri
coloni
count
whether
repres
uniqu
properti
sialidas
simpli
lower
bacteri
count
associ
lower
viral
titer
known
phase
studi
complet
although
yet
report
phase
ii
studi
current
way
clinicaltrialsgov
identifi
favipiravir
previous
known
pyrazin
analogu
inhibit
influenza
viru
rna
polymeras
activ
concentrationdepend
gtpcompetit
manner
mous
model
oral
administr
favipiravir
prevent
death
degre
compar
oseltamivir
addit
favipiravir
shown
vivo
efficaci
rang
rna
virus
includ
polioviru
rhinoviru
respiratori
syncyti
viru
arenavir
hemorrhag
fever
western
equin
enceph
viru
west
nile
viru
phase
clinic
trial
initi
healthi
adult
volunt
januari
japan
phase
ii
studi
infect
patient
initi
octob
clinicaltrialsjp
identifi
phase
ii
studi
older
popul
uncompl
influenza
set
begin
earli
clinicaltrialsgov
identifi
periexposur
nonspecif
activ
innat
immun
use
therapeut
viral
mimet
pathogenassoci
molecular
pattern
pamp
polyiclc
may
provid
immedi
protect
broad
varieti
pathogen
includ
influenza
time
activ
key
element
adapt
immun
bridg
gap
earli
nonspecif
longerterm
specif
host
defens
system
polyiclc
clinic
activ
dsrna
consist
two
homopolym
poli
poli
c
stabil
polyllysin
stabil
increas
resist
endogen
ribonucleas
hydrolysi
severalfold
polyiclc
may
act
induct
dsrnadepend
synthas
rna
helicas
enzym
system
tolllik
receptor
earli
downstream
effect
includ
induct
interferon
beta
interleukin
mous
model
two
dose
polyiclc
mgkg
per
dose
administ
intranas
within
day
prior
infect
ld
influenza
viru
fulli
protect
mice
death
polyiclc
prevent
infect
viru
titer
hemagglutin
plaqu
assay
show
log
decreas
lung
homogen
pretreat
mice
compar
lung
nonpretr
group
efficaci
demonstr
day
prior
infect
addit
anim
studi
demonstr
efficaci
varieti
viral
pathogen
includ
sar
smallpox
viral
agent
mechan
action
depend
viru
even
know
caus
viru
outbreak
topic
polyiclc
may
effect
firstrespons
medic
agent
combin
specif
vaccin
antivir
segreg
intervent
program
due
potenti
intranas
polyiclc
enter
clinic
studi
phase
dosefind
safeti
studi
healthi
volunt
recent
complet
enrol
clinicaltrialsgov
identifi
last
year
limit
armamentarium
effect
antiinfluenza
agent
becom
evid
multipl
new
strategi
develop
attempt
improv
treatment
influenza
influenza
infect
selflimit
although
current
antivir
fail
mitig
morbid
signific
socioeconom
impact
still
associ
diseas
new
drug
strategi
come
fruition
critic
defin
popul
best
util
influenza
viru
replic
cycl
site
novel
antivir
target
note
dark
box
